Background: There are several modalities of coronary artery revascularization for multivessel coronary artery disease. Hybrid coronary revascularization (HCR) with minimally invasive direct coronary artery bypass grafting was introduced for high-risk patients, and recently, many centers have been using it. Limited incisional full sternotomy coronary artery bypass (LIFCAB) involves left internal thoracic artery (LITA)-to-left anterior descending coronary artery (LAD) anastomosis through a sternotomy with a minimal skin incision; it could be considered another technique for minimally invasive LITA-to-LAD anastomosis. Our center has performed HCR using LIFCAB, and in this paper, we report our short-term results, obtained in the past 3 years. Methods: The medical records of 38 patients from May 2010 to June 2013 were analyzed retrospectively. The observation period after HCR was 1 to 37 months (average, 18.3±10.3 months). The patency of revascularization was confirmed with postoperative coronary angio-computerized tomography or coronary angiography. Results: There were 3 superficial wound complications, but no mortalities. All the LITA-to-LAD anastomoses were patent in the immediate postoperative and follow-up studies, but stenosis was detected in 3 cases of percutaneous coronary intervention. Conclusion: HCR using LIFCAB is safe and yields satisfactory results from the viewpoint of revascularization for multivessel disease.
INTRODUCTION
Coronary artery revascularization for multivessel disease can be managed through various modalities, and the patency of left internal thoracic artery (LITA)-to-left anterior descending artery (LAD) anastomosis is the best among the options.
Recent reports have noted a 10-year patency rate of 95% to 98% [1, 2] . The patency of percutaneous coronary intervention (PCI) is enhanced by using drug-eluting stents (DESs). In the
Randomized Comparison of a Sirolimus-Eluting Stent with a
Standard Stent for Coronary Revascularization trial, PCI using DESs yielded free rates from target lesion revascularization at 1, 3, and 5 years of 99%, 93.8%, and 89.7%, respectively [3] .
Hybrid coronary revascularization (HCR) for multivessel disease was introduced in the mid-1990s [4] . HCR is a combination method of grafting surgery using LITA of the LAD lesion with PCI of the remaining lesions. Because the procedure-related morbidity and mortality are lower than those Values are presented as mean±standard deviation or number (%). with conventional coronary artery bypass grafting (CABG), interest in HCR has recently increased. Previous studies reported that the mortality rate associated with HCR was low.
In particular, for high-risk patients, HCR was found to be safer and more effective [5, 6] .
Minimally invasive direct coronary artery bypass grafting (MIDCAB) is usually performed through a 5-to 10-cm left anterolateral thoracotomy. There are advantages of this procedure compared with conventional CABG, which are better cosmetic outcomes, no morbidity of cannulation or cardiopulmonary bypass, and faster recovery [7, 8] . However, in the cases wherein patients were hemodynamically unstable during the operation, switching to conventional CABG was difficult. The conversion rate to conventional sternotomy during MIDCAB was 1.8%, and the risk of morbidity and mortality increased with the conversion [9] . Therefore, we began with the safer minimally invasive coronary artery bypass surgery of limited incisional full sternotomy coronary artery bypass surgery (LIFCAB). LIFCAB involved LITA-to-LAD anastomosis through a sternotomy with a minimal skin incision. The surgeon could create a classic view through the sternotomy, and it was easy to convert to conventional CABG when the patient was hemodynamically unstable. We have used LIFCAB since 2010 and performed HCR using LIFCAB. Therefore, in this paper, we report the short-term results of HCR using LIFCAB. Table 1 .
METHODS
HCR was defined as LITA-to-LAD grafting and PCI to a non-LAD lesion during the same hospitalization period. We included patients with high risk for PCI of LAD lesions because of diffuse stenosis or severe calcification. PCI was possible in lesions other than LAD.
LIFCAB involved off-pump CABG surgery through a full sternotomy and small skin incision (range, 5 to 7 cm) ( from the point of 1 to 1.5 cm above the internipple line to about 6 cm lower, around the xyphoid process. The subcutaneous tissue was softly separated from the muscle layer with electrocautery until the sternal notch, thus making it easier to perform a full sternotomy. The sternal notch was dissected easily with a right-angled clamp without the fear of bleeding.
After the entire sternum was exposed, sternotomy was performed as the second step. First, after marking the median line of the sternum with electrocautery, usual sternotomy was performed from the xyphoid process to the upper end of the skin incision. A small separation of the sternum was retracted with an Army-Navy retractor, and upper sternotomy was performed with an oscillating saw (Fig. 2) . The fibrous band in the sternal notch was incised for achieving full separation of the sternum. A full pericardiotomy was performed to evaluate the gross state of the heart. With the help of an ordinary retractor, the LITA was harvested as pedicled graft by using a harmonic scalpel, and in some cases, the proximal LITA was 
RESULTS
All cases except one were performed electively. In one emergency case, PCI was performed on the right coronary artery before the operation due to acute myocardial infarction.
In all cases, HCR was completed without major complications or mortality, but there were two superficial wound infections and one case of wound dehiscence. The target vessels for PCI are listed in Table 2 . The mean number of DESs used for PCI was 1.34±0.71, and the diameter and the length of the lesion were 3.08±0.65 mm and 21.66±8.13 mm, respectively.
The conversion to CABG using CPB was unnecessary. The Values are presented as mean±standard deviation or number (%). Initial: first coronary angio-computed tomography or coronary angiography after HCR.
stinitis, but there were occurrences of superficial wound infection and dehiscence (Table 3 ). All patients were successfully followed up for 18.3±10.3 months (range, 1 to 37 months) after HCR. All of the LITAs were patent in the follow-up coronary angio-CT or angiography. However, for three patients who suffered from newly developed chest pain during the follow-up, one in the left circumflex artery and two in the right coronary artery, restenosis was confirmed within a year. These patients were retreated with PCI as soon as possible (Table 4) .
DISCUSSION
In patients with multivessel disease, conventional CABG was one of the standard treatments [10] . The 5-year patency rates of the LITA-LAD were between 92% and 99%, and the 10-year patency rates were between 95% and 98% [2, 14, 15] .
The recent PREVENT IV (project of ex-vivo vein graft engineering via transfection IV) and PRAGUE-4 (primary angioplasty in patients transferred from general community hospitals to specialized PTCA units with or without emergency thrombolysis-4) trials reported vein graft patency rates of 50% to 75% after 1 year [16] [17] [18] . Despite the improvement in various aspects of conventional CABG, it carries the risk of peri-and postoperative complications and mortality concerning cannulation and CPB [11] [12] [13] . Elderly patients with comorbidities were at greater risk, so HCR was introduced as an alternative treatment.
Angelini et al. [4] reported the first HCR of 6 cases of MIDCAB to LITA-LAD combined with PCI to non-LAD vessels. Many centers now perform HCR for multivessel disease, and the American College of Cardiology Foundation and the American Heart Association have recommended HCR for selected patients on level of evidence B for limitation to traditional CABG, lack of suitable graft conduits, or unfavorable LAD artery for PCI [19] .
MIDCAB offers the advantage of not needing a greater amount of anticoagulant than conventional CABG with CPB [11] , but the surgeon has to work within limited fields, and it is difficult to convert MIDCAB to conventional CABG when the patient is hemodynamically unstable [20] . In a previous study, the conversion rate to sternotomy was approximately 2% in MIDCAB [9] . In contrast, the conversion to conventional CABG in LIFCAB is easier than in MIDCAB through just extending a wound. In fact, one case of LIFCAB converted to on-pump beating CABG, but we simply extended the skin incision and then performed the procedure without any problems. Because the operative field of LIFCAB is similar to that of conventional CABG, the learning curve for beginners is shorter and they can properly perform a classical view for the anastomosis. In addition, mobilizing the LITA is convenient in LIFCAB, so the time required for harvesting the LITA is reduced. We have performed HCR using LIFCAB since 2010. Our short-term mortality and morbidity outcomes have been satisfactory. The patency of the LITA-to-LAD anastomosis was confirmed, and our results did not differ from those of MIDCAB, which are reported to be 93% to 100% [1] . We performed this operation with a 7-cm skin incision in the first few cases and were able to gradually reduce the length of the skin incision with experience. We now operate with a 5-to 6-cm skin incision without diffi-− 110 − culty. Sternotomy is associated with a greater risk of bleeding and mediastinitis than thoracotomy, but in this study, complications such as bleeding or mediastinitis did not occur.
The operation time was not too long, and all patients could be weaned from mechanical ventilation within 6 hours postoperatively. Despite sternotomy, we believe that LIFAB is a minimally invasive surgery procedure and is suitable for HCR.
Due to the small size of our sample, we cannot compare the results with those of conventional CABG. In this paper, we reported the short-term results of HCR using LIFCAB. In future, we intend to report long-term results and conduct a study comparing it with conventional CABG for multivessel disease. In conclusion, HCR using LIFCAB is a safe and feasible new technique.
